Amplia Therapeutics Limited
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develo… Read more
Amplia Therapeutics Limited (INNMF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.186x
Based on the latest financial reports, Amplia Therapeutics Limited (INNMF) has a cash flow conversion efficiency ratio of -0.186x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.00 Million) by net assets ($42.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Amplia Therapeutics Limited - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Amplia Therapeutics Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Amplia Therapeutics Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amplia Therapeutics Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hank Payments Corp.
PINK:HNKPF
|
0.444x |
|
Target Global Acquisition I Corp
PINK:TGAA
|
0.000x |
|
TGAAF
PINK:TGAAF
|
0.000x |
|
Kamat Hotels (I) Limited
NSE:KAMATHOTEL
|
0.096x |
|
Taya Vietnam Electric Wire and Cable JSC
VN:TYA
|
N/A |
|
KIOCL Limited
NSE:KIOCL
|
-0.010x |
|
Titania Holding AB Series B
ST:TITA-B
|
-0.051x |
|
HEALTH NET
F:HNT
|
N/A |
Annual Cash Flow Conversion Efficiency for Amplia Therapeutics Limited (2010–2025)
The table below shows the annual cash flow conversion efficiency of Amplia Therapeutics Limited from 2010 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $21.02 Million | $-6.89 Million | -0.328x | +27.06% |
| 2024-03-31 | $11.42 Million | $-5.13 Million | -0.449x | -34.42% |
| 2023-03-31 | $15.84 Million | $-5.29 Million | -0.334x | -65.79% |
| 2022-03-31 | $21.85 Million | $-4.40 Million | -0.201x | +28.56% |
| 2021-03-31 | $10.34 Million | $-2.92 Million | -0.282x | -16.24% |
| 2020-03-31 | $8.61 Million | $-2.09 Million | -0.243x | -112.92% |
| 2019-03-31 | $8.66 Million | $-987.35K | -0.114x | +92.41% |
| 2018-03-31 | $2.36 Million | $-3.55 Million | -1.501x | -61.48% |
| 2017-03-31 | $6.63 Million | $-6.16 Million | -0.930x | +21.06% |
| 2016-03-31 | $4.00 Million | $-4.71 Million | -1.178x | -44.06% |
| 2015-03-31 | $4.87 Million | $-3.98 Million | -0.817x | -397.85% |
| 2014-03-31 | $9.77 Million | $-1.60 Million | -0.164x | -5.13% |
| 2013-03-31 | $11.23 Million | $-1.75 Million | -0.156x | +60.77% |
| 2012-03-31 | $3.19 Million | $-1.27 Million | -0.398x | -50.85% |
| 2011-03-31 | $6.07 Million | $-1.60 Million | -0.264x | +22.54% |
| 2010-03-31 | $5.98 Million | $-2.04 Million | -0.341x | -- |